Q1 FY27 Results: Revenue up 35% YoY but Profit slips 5% on margin pressure

Revenue growth above 20%EBITDA margin compressionRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+12.4%Reaction day

₹10.80

prior close

₹10.77

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+12.3% vs market

Pharmaceuticals peers, median of 167sector-0.4%+12.8% vs sector

On the reaction day the stock moved 12.3 pts more than Nifty Microcap 250 and 12.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.5

10m

-0.2

15m

+6.5

30m

+9.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+12.4+0.1+12.3-0.4+12.8

Next day

+10.6+0.5+10.1-0.0+10.7

+9.0-0.1+9.1-0.8+9.7

+9.6+0.4+9.2-0.5+10.1

+18.1+0.7+17.4-0.8+18.8

+11.1+0.9+10.2-0.6+11.8

+12.9+1.1+11.8-0.8+13.7

15d

+9.1+1.6+7.5+1.2+7.9

-3.1-0.7-2.4+0.6-3.7

-15.7-3.2-12.5-4.1-11.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue from operations grew 35% YoY to Rs 3,467.79 lakh (vs Rs 2,564 lakh). However, standalone net profit dipped 4.7% to Rs 395.53 lakh (vs Rs 414.95 lakh) as input and overhead costs rose faster than sales, compressing margins. Consolidated revenue rose to Rs 3,984.17 lakh and consolidated PAT at Rs 466.64 lakh. Standalone EPS at Rs 0.163 vs Rs 0.179 YoY. No exceptional items. Limited review report from R Pugalia and Company is unqualified. Single segment: Bulk Drugs, Biotech Products and Intermediates.

Likely market impact

Topline growth is encouraging but weak profitability and shrinking margins may limit near term investor enthusiasm.